FDA approves RevMed’s Rasonque to slow pancreatic cancer
In a late-stage study, RevMed’s Rasonque helped subjects live to 13 months, nearly twice as long as chemotherapy alone. US regulators approved the drug to slow pancreatic cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.